TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 1430708
Drug: Inhaled indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhaled indomethacin (25 mg and 50 mg)
Study: 6539002
Drug: Stanozolol 50
Normalized name: stanozolol 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stanozolol 50 mg intramuscularly 24 hr before surgery
Study: 3524929
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate (TU) 240 mg orally for 12 weeks
Study: 29046302
Drug: Tea administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea administered simultaneously with the meal (TM-2)
Study: 29046302
Drug: Tea administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea administered 1 hour postmeal (TM-3)
Study: 29046302
Drug: Water administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water administered with the meal (TM-1)
Study: 14694916
Drug: Air (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Air (5 L/min)
Study: 10869641
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine (2 mg, dose-optimization schedule)
Study: 10869641
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine (5 mg, fixed-dose)
Study: 10869641
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine (6 mg, fixed-dose)
Study: 10869641
Drug: Sublingual apomorphine
Normalized name: apomorphine Sublingual Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual apomorphine (all doses)
Study: 1607415
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% cream, applied twice daily for 1 week
Study: 4026357
Drug: Frusemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frusemide (1 mg/kg) administered intravenously at approximately 24 hour intervals for three doses.
Study: 24305905
Drug: Peer support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peer support workers (PSWs) trained over 12 weekly, 1-day sessions from April to July 2010.
Study: 10502583
Drug: Topical ofloxacin
Normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical ofloxacin
Study: 16231265
Drug: 28-day regimen
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 28-day regimen of antiretroviral therapy and counseling
Study: 7755228
Drug: 50 g
Normalized name: glucose 50 g/296 mL oral liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 g of alcohol
Study: 21790621
Drug: Liberal transfusion
Normalized name: dextromethorphan
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liberal transfusion strategy (RBCs if Hb concentration was 95 g/L or less during CPB and less than 100 g/L postoperatively)
Study: 17981847
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (5 hours/week for 12 weeks)
Study: 17981847
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (2 hours/week for 12 weeks)
Study: 27599039
Drug: IMM-101 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: IMM-101 (10 mg/ml intradermally) + GEM (1000 mg/m² intravenously)
Study: 25409371
Drug: Oral diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diet initiated 72 hours after presentation (on-demand group)
Study: 18829392
Drug: MLN0002 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MLN0002 0.5 mg/kg
Study: 7361704
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg thiamin hydrochloride
Study: 25543425
Drug: Dog days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dog days moxibustion plaster therapy
Study: 25543425
Drug: Beclometasone dipropionate
Normalized name: Beclometasone dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Beclometasone dipropionate aqueous nasal spray
Study: 20938662
Drug: R-CHOP treatment
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP treatment in IDO-positive DLBCL
Study: 20938662
Drug: R-CHOP treatment
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: R-CHOP treatment in IDO-negative DLBCL
Study: 10517729
Drug: Enoxaparin (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (initial 30 mg intravenous bolus followed by 1.0 mg/kg every 12 hours; outpatient phase: 40 mg for patients <65 kg and 60 mg for patients ≥65 kg)
Study: 10517729
Drug: Unfractionated heparin
Normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Unfractionated heparin (UFH) for ≥3 days followed by subcutaneous placebo injections
Study: 363977
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg of clomipramine given three times a day
Study: 24029539
Drug: Short-term group
Normalized name: hydrogen peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Short-term group therapy (20 weekly, 90 min sessions)
Study: 21890888
Drug: rFVIIa (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (10 μg/kg)
Study: 21890888
Drug: rFVIIa (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rFVIIa (20 μg/kg)
Study: 19278128
Drug: Nicotine polacrilex
Normalized name: Nicotine Polacrilex
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine polacrilex (6 mg)
Study: 15250816
Drug: Manualized therapies
Normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manualized therapies
Study: 8845601
Drug: Calcium augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium augmentation (1700 mg)
Study: 8845601
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) with dietary calcium augmentation
Study: 28119138
Drug: Kg‐Free intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kg‐Free intervention (10 weekly group sessions plus 2 booster fortnightly sessions, 2h30 each)
Study: 25938187
Drug: Mindfulness and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness and acceptance-based group therapy (MAGT)
Study: 23337838
Drug: Statin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Statin therapy for 8 months
Study: 22002336
Drug: Irbesartan (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (300 mg) after 14 days
Study: 22002336
Drug: Aliskiren (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren (300 mg) after 14 days
Study: 9240180
Drug: Psychosocial intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychosocial intervention (weekly counselling 4-9 weeks after surgery)
Study: 22109763
Drug: Antibiotic/steroid treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic/steroid treatment
Study: 3908509
Drug: Modified Goeckerman
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Goeckerman regimen with hydrocortisone valerate cream
Study: 3908509
Drug: Modified Goeckerman
Approvals — FDA: no, EMA: no, PMDA: no
Description: Modified Goeckerman regimen with vehicle cream
Study: 21323540
Drug: Conventional laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional laser therapy
Study: 29680006
Drug: Intraprostatic injections
Normalized name: ALCOHOL 80 mL in 100 mL INTRAPROSTATIC LIQUID [80% Alcohol Hand Sanitizer]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraprostatic injections of onabotulinumtoxinA (200 U)
Study: 24193238
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg (Group A)
Study: 10599951
Drug: Deramciclane 30
Normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane 30 mg
Study: 10599951
Drug: Deramciclane 60
Normalized name: Deramciclane
DrugBank: Deramciclane (DB06512)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane 60 mg
Study: 10760840
Drug: Deramciclane (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deramciclane (all doses)
Study: 6289447
Drug: Prolonged course
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged course of chemotherapy (41 weeks) combining adriamycin, methotrexate in high doses followed by folinic acid, vincristine, and cyclophosphamide
Study: 30784924
Drug: Xinkeshu tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xinkeshu tablets
Study: 25534369
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose tDCS
Study: 25534369
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose tDCS
Study: 10347354
Drug: Crown type
Normalized name: collagen type I
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crown type G (gold alloy)
Study: 7493435
Drug: Antecedent hypoglycaemia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antecedent hypoglycaemia (2.5 mmol/l)
Study: 6244414
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose daily macrocrystals of nitrofurantoin
Study: 6244414
Drug: Intravesical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical treatment and oral nitrofurantoin
Study: 25991758
Drug: Protocolised algorithm
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protocolised algorithm using stroke volume variation to guide fluid administration
Study: 23471488
Drug: Active pellets
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active pellets (5 g, 47% lauric acid by weight)
Study: 19351658
Drug: Intranasal 350
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 350 microg 17beta-estradiol + 550 microg norethisterone
Study: 19351658
Drug: Intranasal 350
Normalized name: NALOXONE RESCUE KIT INTRANASAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal 350 microg 17beta-estradiol + 50 or 175 microg norethisterone
Study: 19351658
Drug: Intranasal regimens
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal regimens
Study: 19351658
Drug: Oral 2
Normalized name: SYRINGE,ORAL 20ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral 2 mg 17beta-estradiol + 1 mg norethisterone
Study: 18006769
Drug: ABT‐510 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐510 10 mg twice daily
Study: 18006769
Drug: ABT‐510 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT‐510 100 mg twice daily
Study: 30378311
Drug: EGFR-TKIs plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGFR-TKIs plus Traditional Chinese Medicine (TCM)
Study: 26944733
Drug: Dabigatran 150
Normalized name: dabigatran 150 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 150 mg twice a day (D150)
Study: 26944733
Drug: Dabigatran 110
Normalized name: dabigatran 110 mg oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dabigatran 110 mg twice a day (D110)
Study: 16165400
Drug: Levetiracetam (LEV)
Normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levetiracetam (LEV) 1000 mg twice daily for 9 days
Study: 28210808
Drug: Levalbuterol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levalbuterol (2.5 mg)
Study: 12714797
Drug: Selegiline treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selegiline treatment
Study: 6366823
Drug: Pentobarbitone (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentobarbitone (100 mg)
Study: 29774477
Drug: Cefepime (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime (2 g q8h for adults and 50 mg/kg q8h for children)
Study: 29774477
Drug: Cefoperazone/sulbactam plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefoperazone/sulbactam plus amikacin (CS + A) (2 g q8h for adults and 50 mg/kg q8h for children plus amikacin 15 mg/kg once a day)
Study: 23901043
Drug: No steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: No steroid treatment (Control)
Study: 10068969
Drug: Ketoprofen (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (1 mg W kg‐1)
Study: 10068969
Drug: Pethidine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pethidine (1 mg W kg‐1)
Study: 10068969
Drug: Saline (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline (0.1 ml W kg‐1)
Study: 8657963
Drug: Dry boldo
Normalized name: Boldo
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dry boldo extract (2.5 g)
Study: 1646369
Drug: Interferon alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon alpha-2b treatment for 9 months
Study: 30765762
Drug: Placebo with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo with calcium carbonate 300 mg daily
Study: 30765762
Drug: Bushen Yijing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bushen Yijing Fang (BSYJF) with calcium carbonate 300 mg daily
Study: 21550158
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) gel applied to the socket of the third molar
Study: 19117316
Drug: OK-432 immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 immunotherapy (four-dose intralesional injection series at eight-week intervals)
Study: 19117316
Drug: OK-432 immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 immunotherapy (for microcystic LM)
Study: 19117316
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment group (observational controls)
Study: 19117316
Drug: OK-432 immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 immunotherapy
Study: 19117316
Drug: OK-432 immunotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OK-432 immunotherapy vs historical surgical data on LM
Study: 1487229
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g propacetamol HCl given intravenously over a 15‐min period
Study: 30854571
Drug: Light blue
Normalized name: opaspray light blue (TM)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Light blue gel nail polish using Masimo oximeter
Study: 30854571
Drug: Orange gel
Normalized name: Octinoxate 2.5% Topical application Gel/Jelly [BAIN DE SOLEIL ORANGE GELEE]
DrugBank: Orange (DB10549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Orange gel nail polish using Masimo oximeter
Study: 30854571
Drug: Black gel
Normalized name: acid black 52
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black gel nail polish using Philips oximeter
Study: 22699097
Drug: Forced-use therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Forced-use therapy (FUT) program
Study: 11836286
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg daily for 3 months, followed by 20 mg daily for 3 months)
Study: 11836286
Drug: Atorvastatin (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (10 mg and 20 mg)
Study: 10094169
Drug: Prednisolone (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisolone (20 mg b.i.d. IV/IM initially, decreasing over 40 days) with antituberculosis treatment
Study: 10094169
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antituberculosis treatment only)
Study: 7593627
Drug: Inhaled methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methacholine (increasing concentrations); no deep inspirations allowed
Study: 7593627
Drug: Inhaled methacholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methacholine (increasing concentrations); deep inspirations initiated
Study: 2119303
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of phenytoin (PHT)
Study: 11128246
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of carbamazepine (CBZ)
Study: 2119303
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (continued existing therapy)
Study: 27859395
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid at a dosage of 10 mg/kg, administered 4-9 hours preoperatively
Study: 27859395
Drug: 5-aminolevulinic acid
Normalized name: 5-aminolevulinic acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-aminolevulinic acid at a dosage of 1 mg/kg
Study: 23906938
Drug: Calcineurin inhibitor
Normalized name: Calcineurin inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcineurin inhibitor and/or mycophenolate sodium (n=20)
Study: 17367093
Drug: AVINZA (morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVINZA (morphine sulfate extended-release capsules)
Study: 17367093
Drug: OxyContin (oxycodone
Approvals — FDA: no, EMA: no, PMDA: no
Description: OxyContin (oxycodone hydrochloride controlled-release tablets)
Study: 14644065
Drug: Progesterone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progesterone (200 mg, intramuscular injection)
Study: 2468862
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg nitrendipine (sublingually)
Study: 2468862
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg nifedipine (sublingually)
Study: 27109450
Drug: Topiroxostat 120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 120 mg/day
Study: 27109450
Drug: Allopurinol 200
Normalized name: allopurinol 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol 200 mg/day
Study: 22141217
Drug: Fascia iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia iliaca compartment block with 0.1% bupivacaine at a rate of 10 mL/h
Study: 22141217
Drug: Continuous epidural
Normalized name: ACCU-BLOC PERIFIX CONTINUOUS EPIDURAL ANESTHESIA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous epidural analgesia with 0.1% bupivacaine in continuous infusion at a rate of 8 mL/h
Study: 16839319
Drug: Bremelanotide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bremelanotide (20 mg, single intranasal dose)
Study: 12571655
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g American ginseng (AG)
Study: 23303043
Drug: TC-5619 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: TC-5619 (1 mg day 1 to week 4, 5 mg week 4 to 8, and 25 mg week 8 to 12)
Study: 19105416
Drug: Velcade therapy
Normalized name: Velcade
DrugBank: Bortezomib D-mannitol (DB16741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Velcade therapy
Study: 16406171
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of split, trivalent influenza vaccine
Study: 16406171
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of split, trivalent influenza vaccine
Study: 16406171
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of split, trivalent influenza vaccine (females)
Study: 16406171
Drug: Subcutaneous injection
Normalized name: EPINEPHRINE 0.3 mg SUBCUTANEOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous injection of split, trivalent influenza vaccine (females)
Study: 15592191
Drug: Dipyridamole (0.74
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dipyridamole (0.74 mg/kg) sestamibi imaging
Study: 1867962
Drug: Intravenous cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous cisapride 10 mg
Study: 3691273
Drug: Oral cisapride
Normalized name: Cisapride
DrugBank: Cisapride (DB00604)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cisapride 20 mg
Study: 20040335
Drug: Methotrexate (MTX)
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) at a dose of 2 ‐ 3.5 g/m(2)
Study: 29536782
Drug: 0.1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg/kg of oxycodone (Group O)
Study: 29536782
Drug: 1 µg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 µg/kg of fentanyl (Group F)
Study: 19454920
Drug: Family-focused therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-focused therapy for adolescents (FFT-A)
Study: 17436601
Drug: Low-dose step-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose step-up OI protocol with weekly increments of 25 IU/day rFSH
Study: 15545098
Drug: Botox injections
Normalized name: Botox
DrugBank: DaxibotulinumtoxinA (DB17929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Botox injections (18 units per area) with ablative laser resurfacing
Study: 8299664
Drug: Felodipine 20
Normalized name: Felodipine
DrugBank: Felodipine (DB01023)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Felodipine 20 mg
Study: 3415888
Drug: Saline by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline by infusion pump plus morphine 10 mg/70 kg s.c. (Control)
Study: 29047215
Drug: 103 mg
Normalized name: valsartan 103 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 103 mg of p-synephrine (S)
Study: 29047215
Drug: 233 mg
Normalized name: kava root 233 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 233 mg of caffeine + 104 mg of p-synephrine (LC + S)
Study: 29047215
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg of caffeine (LC)
Study: 29047215
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg of caffeine (HC)